Skip to main navigationSkip to main content
The University of Southampton

Dr Thomas Cummin MRCP, MBBCh, BSc (First Hons)

Clinical Research Fellow (Lymphoma), Specialist Registrar in Haematology

Dr Thomas Cummin's photo

Dr Thomas Cummin is a Clinical Research Fellow (Lymphoma) in Cancer Sciences

Undergraduate medical training at University of Wales College of Medicine to obtain MBBCh which involved a period of research at Cardiff University involving novel candidate genes in animal models for ADHD with the Behavioral Genetics Group achieving a 1st class BSc (hons).

Subsequent medical training at University Hospital of Wales and Royal Gwent Hospital for Foundation Program and medical specialisation obtaining MRCP in 2012.

In 2013 began Haematology specialty training at University Hospital Southampton. Interruption in specialty training for special interest in lymphoma. In 2016 began research in diffuse-large B-cell lymphoma at Southampton University.


MRCP, Royal College of Physicians (2011)
MBBCh, University of Wales College of Medicine (2009)
BSc 1st hons, Psychology in Medicine (2008)
FRCPath part one, Royal College of Pathologists (2015)

Appointments held

Clinical Research Fellow (Lymphoma) Southampton University/ University Hospital Southampton 2016 to present

Haematology Specialty Registrar, University Hospital Southampton, Royal Bournemouth Hospital and Poole General Hospital 2013-2016

Core Medical Trainee, University Hospital of Wales and Royal Gwent Hospital 2011-2013

Foundation Programme Trainee, University Hospital or Wales 2009-2011




Research interests

More than 10,000 new cases of non-Hodgkin’s lymphoma (NHL) are diagnosed in the UK with approximately 4,500 attributable deaths each year. In the Western World, diffuse large B-cell lymphoma (DLBCL) comprises one third of all adult NHL cases, accounting for an annual incidence in the UK of approximately 3,000 patients. Those patients that do not respond to, or are not fit enough for, standard treatment require improved treatment regimes to improve chance of cure. Recent advances in our understanding of the biology of DLBCL and development of novel agents provide an opportunity to improve outcomes for patients.

Based at the University of Southampton, investigating precision medicine in diffuse-large B-cell lymphoma (DLBCL). Involvement in early phase to phase III clinical trials at Southampton Clinical Trials Unit.

Precision Medicine for Aggressive Lymphoma Consortium Member. Researchers from HMDS (Haematological Malignancy Diagnostic Service), University of Oxford, University of Cambridge, St Bartholomew’s University and University of Southampton. Development and validation of robust predictive molecular assays for use in stratification. Developing assays for longitudinal analysis and clonal evolution. Bioinformatics and statistics. Prospective testing of stratified therapy with novel agents.





Research group

Cancer Sciences


Honorary NHS Trust Contract- University Hospital Southampton

Clinical Research Fellow University of Southampton/ Southampton Clinical Trials Unit

Precision Medicine for Aggressive Lymphoma Consortium



Dr Thomas Cummin
Tel: 023 8120 4128
Fax: 0844 7740621
Share this profile Share this on Facebook Share this on Twitter Share this on Weibo
Privacy Settings